Volume 9, Issue 11
Article

Quality adjusted survival analysis

P. P. Glasziou

Department of Public Health, University of Sydney, Sydney, Australia

Search for more papers by this author
R. J. Simes

NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

Search for more papers by this author
R. D. Gelber

Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, U.S.A.

Search for more papers by this author
First published: November 1990
Citations: 197

Abstract

We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival.

If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re‐analysis of a large three‐arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in post‐menopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option.

Number of times cited according to CrossRef: 197

  • Research Methods: Clinical Trials in Geriatric Oncology, Geriatric Oncology, 10.1007/978-3-319-57415-8, (1063-1076), (2020).
  • Dynamic inference for non‐Markov transition probabilities under random right censoring, Scandinavian Journal of Statistics, 10.1111/sjos.12443, 47, 2, (572-586), (2020).
  • Estimation of Quality-Adjusted Life Expectancy of Oral Cancer Patients: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements, Value in Health Regional Issues, 10.1016/j.vhri.2019.07.005, 21, (59-65), (2020).
  • Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China, Clinical Therapeutics, 10.1016/j.clinthera.2020.08.018, (2020).
  • The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2020.20045, (1-6), (2020).
  • Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model, Advances in Therapy, 10.1007/s12325-020-01418-7, (2020).
  • Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib, Cancer, 10.1002/cncr.33168, 0, 0, (2020).
  • Semiparametric regression methods for temporal processes subject to multiple sources of censoring, Canadian Journal of Statistics, 10.1002/cjs.11528, 48, 2, (222-237), (2019).
  • R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment, Value in Health, 10.1016/j.jval.2019.01.003, 22, 5, (575-579), (2019).
  • The Use of “Quality-Adjusted Life Years” (QALYs) to Evaluate Treatment in Intensive Care, Anaesthesia and Intensive Care, 10.1177/0310057X9502300309, 23, 3, (322-331), (2019).
  • Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer, Breast Cancer Research and Treatment, 10.1007/s10549-018-05107-6, (2019).
  • A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck, PharmacoEconomics, 10.1007/s40273-019-00798-1, (2019).
  • Estimating the quantile medical cost under time-dependent covariates and right censored time-to-event variable based on a state process, Statistical Methods in Medical Research, 10.1177/0962280219882968, (096228021988296), (2019).
  • Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2018.24.6.514, 24, 6, (514-523), (2018).
  • The appropriateness of coronary investigation in myocardial injury and Type 2 myocardial infarction (ACT-2): A randomized trial design, American Heart Journal, 10.1016/j.ahj.2018.09.016, (2018).
  • Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis, Therapeutic Advances in Medical Oncology, 10.1177/1758835918788500, 10, (175883591878850), (2018).
  • Quantifying the totality of treatment effect with multiple event‐time observations in the presence of a terminal event from a comparative clinical study, Statistics in Medicine, 10.1002/sim.7907, 37, 25, (3589-3598), (2018).
  • Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer, PharmacoEconomics, 10.1007/s40273-018-0752-0, (2018).
  • Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment, PharmacoEconomics, 10.1007/s40273-017-0583-4, 36, 1, (7-15), (2017).
  • Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial, European Journal of Cancer, 10.1016/j.ejca.2017.07.008, 84, (27-33), (2017).
  • A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study, American Heart Journal, 10.1016/j.ahj.2017.05.004, 190, (25-33), (2017).
  • Research Methods: Clinical Trials in Geriatric Oncology, Geriatric Oncology, 10.1007/978-3-319-44870-1, (1-14), (2017).
  • QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer, ESMO Open, 10.1136/esmoopen-2017-000284, 2, 5, (e000284), (2017).
  • Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial, ESMO Open, 10.1136/esmoopen-2017-000261, 2, 5, (e000261), (2017).
  • Nonparametric Two‐Sample Tests of the Marginal Mark Distribution with Censored Marks, Scandinavian Journal of Statistics, 10.1111/sjos.12265, 44, 2, (545-562), (2017).
  • Evaluating Utility Measurement From Recurrent Marker Processes in the Presence of Competing Terminal Events, Journal of the American Statistical Association, 10.1080/01621459.2016.1166113, 112, 518, (745-756), (2017).
  • Nonparametric Benefit–Risk Assessment Using Marker Process in the Presence of a Terminal Event, Journal of the American Statistical Association, 10.1080/01621459.2016.1180988, 112, 518, (826-836), (2017).
  • Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling, Medical Decision Making, 10.1177/0272989X16670617, 37, 4, (427-439), (2016).
  • Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2015.11.005, 125, (79-87), (2016).
  • Impact of nine chronic conditions for US adults aged 65 years and older: an application of a hybrid estimator of quality-adjusted life years throughout remainder of lifetime, Quality of Life Research, 10.1007/s11136-016-1226-5, 25, 8, (1921-1929), (2016).
  • Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial, The Lancet Gastroenterology & Hepatology, 10.1016/S2468-1253(16)30003-6, 1, 1, (15-24), (2016).
  • The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial, Value in Health, 10.1016/j.jval.2016.01.013, 19, 4, (431-439), (2016).
  • European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer, European Journal of Cancer, 10.1016/j.ejca.2016.05.013, 63, (168-179), (2016).
  • Estimating the cumulative mean function for history process with time‐dependent covariates and censoring mechanism, Statistics in Medicine, 10.1002/sim.6998, 35, 25, (4624-4636), (2016).
  • Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer , Current Medical Research and Opinion, 10.1185/03007995.2015.1124075, 32, 3, (459-465), (2016).
  • Bayesian Approach to Personalized Benefit-Risk Assessment, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1193045, 8, 3, (316-324), (2016).
  • Patient reported outcomes as endpoints in medical research, Statistical Methods in Medical Research, 10.1191/0962280204sm357ra, 13, 2, (115-138), (2016).
  • Simultaneous analysis of quality of life and survival data, Statistical Methods in Medical Research, 10.1191/0962280202sm269ra, 11, 1, (25-48), (2016).
  • Using inverse-weighting in cost-effectiveness analysis with censored data, Statistical Methods in Medical Research, 10.1191/0962280202sm308ra, 11, 6, (539-551), (2016).
  • Ethical issues in oncology biostatistics, Statistical Methods in Medical Research, 10.1191/0962280202sm301ra, 11, 5, (429-448), (2016).
  • Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT), Health Technology Assessment, 10.3310/hta20440, 20, 44, (1-320), (2016).
  • Nonparametric inference for the joint distribution of recurrent marked variables and recurrent survival time, Lifetime Data Analysis, 10.1007/s10985-015-9347-7, 23, 2, (207-222), (2015).
  • Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder, Molecular Psychiatry, 10.1038/mp.2015.21, 21, 2, (237-242), (2015).
  • Survival Analysis, Health Technology Assessment, 10.1201/b18285, (149-178), (2015).
  • Clinical Trial Design of Maintenance Treatments in Bipolar Disorder, Clinical Trial Design Challenges in Mood Disorders, 10.1016/B978-0-12-405170-6.00001-4, (1-12), (2015).
  • The Price of Nonabandonment: HIV in Resource-Limited Settings, Manufacturing & Service Operations Management, 10.1287/msom.2015.0545, 17, 4, (554-570), (2015).
  • Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios, Statistics in Medicine, 10.1002/sim.6594, 34, 30, (4057-4069), (2015).
  • Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy, Arthritis & Rheumatology, 10.1002/art.39011, 67, 4, (1117-1127), (2015).
  • Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US, Journal of Medical Economics, 10.3111/13696998.2014.985789, 18, 3, (200-209), (2014).
  • Quality‐adjusted time without symptoms or toxicity (Q‐TWiST): patient‐reported outcome or mathematical model? A systematic review in cancer, Psycho-Oncology, 10.1002/pon.3595, 24, 3, (253-261), (2014).
  • Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach, Quality of Life Research, 10.1007/s11136-013-0608-1, 23, 5, (1411-1419), (2014).
  • Study design of embracing high-sensitivity troponin effectively: The value of more information: A randomized comparison, Contemporary Clinical Trials, 10.1016/j.cct.2014.08.012, 39, 2, (183-190), (2014).
  • The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study, European Journal of Cancer, 10.1016/j.ejca.2013.09.028, 50, 3, (535-543), (2014).
  • Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis, Journal of Medical Economics, 10.3111/13696998.2014.903122, 17, 5, (338-346), (2014).
  • Quality of Life, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
  • Quality of Life and Survival Analysis, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
  • References, Statistical Thinking for Non‐Statisticians in Drug Regulation, 10.1002/9781118470961, (331-338), (2014).
  • Quality of Life, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596333, (608-621), (2014).
  • Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value, Expert Review of Anticancer Therapy, 10.1586/era.12.42, 12, 6, (839-854), (2014).
  • Quality-of-life concerns in lung cancer patients, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1586/erp.10.81, 10, 6, (667-676), (2014).
  • Quality-adjusted survival as an end point in breast cancer trials, Clinical Investigation, 10.4155/cli.13.37, 3, 6, (545-555), (2013).
  • Revisit Kaplan–Meier Estimator in Estimating QAL Survival Distributions, Journal of Statistical Theory and Practice, 10.1080/15598608.2013.790235, 7, 3, (496-504), (2013).
  • Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone, SpringerPlus, 10.1186/2193-1801-2-391, 2, 1, (391), (2013).
  • Statistical Issues with Trial Data and Economic Modeling for Cost-Effectiveness Evaluation, Modern Clinical Trial Analysis, 10.1007/978-1-4614-4322-3, (149-166), (2013).
  • Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma, British Journal of Cancer, 10.1038/bjc.2013.298, 109, 1, (8-13), (2013).
  • Quantitative Risk/Benefit Assessment: Where Are We?, Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials, 10.1007/978-1-4614-5245-4_8, (119-135), (2013).
  • Estimating a unitary effect summary based on combined survival and quantitative outcomes, Computational Statistics & Data Analysis, 10.1016/j.csda.2013.03.028, 66, (129-139), (2013).
  • Rejoinder, Journal of the American Statistical Association, 10.1080/01621459.2012.665198, 107, 498, (518-520), (2012).
  • Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States, Journal of Medical Economics, 10.3111/13696998.2012.720319, 15, sup1, (55-64), (2012).
  • Design and Analysis of Quality-of-Life Data, Handbook of Statistics in Clinical Oncology, Third Edition, 10.1201/b11800, (339-368), (2012).
  • Examination of Assumptions in Using Time Tradeoff and Standard Gamble Utilities in Individuals With Spinal Cord Injury, Archives of Physical Medicine and Rehabilitation, 10.1016/j.apmr.2011.08.039, 93, 2, (245-252), (2012).
  • Quality of life and supportive care for patients with metastatic renal cell carcinoma, Cancer and Metastasis Reviews, 10.1007/s10555-012-9357-9, 31, S1, (33-39), (2012).
  • Quality of Life Perspectives in Chronic Disease and Disorder Studies, Handbook of Statistics Volume 28, 10.1016/B978-0-44-451875-0.00016-6, (401-431), (2012).
  • Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer, Journal of Clinical Gastroenterology, 10.1097/MCG.0b013e3182557307, 46, 8, (637-648), (2012).
  • Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma, PharmacoEconomics, 10.2165/11535290-000000000-00000, 28, 7, (577-584), (2012).
  • Q‐TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer, Cancer, 10.1002/cncr.26213, 118, 2, (461-468), (2011).
  • Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic–3 (ASSENT-3) trial, American Heart Journal, 10.1016/j.ahj.2010.12.026, 161, 5, (848-854), (2011).
  • Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma, Journal of Medical Economics, 10.3111/13696998.2011.566296, 14, 2, (245-252), (2011).
  • Health, economic, psychological and social impact of educating carers of patients with advanced pulmonary disease (protocol), Contemporary Clinical Trials, 10.1016/j.cct.2011.05.004, 32, 5, (717-723), (2011).
  • A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer, British Journal of Cancer, 10.1038/bjc.2011.179, 104, 12, (1848-1853), (2011).
  • mTOR inhibition in advanced renal cell carcinoma, Anti-Cancer Drugs, 10.1097/CAD.0b013e3283407dde, 22, 1, (18-23), (2011).
  • Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, 10.1200/JCO.2010.33.9101, 29, 34, (4498-4504), (2011).
  • Estimating the mean of a mark variable under right censoring on the basis of a state function, Computational Statistics & Data Analysis, 10.1016/j.csda.2010.10.028, 55, 4, (1726-1735), (2011).
  • Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib, Current Medical Research and Opinion, 10.1185/03007995.2011.621209, 27, 12, (2245-2252), (2011).
  • Decision analysis in the clinical neurosciences: a systematic review of the literature, European Journal of Neurology, 10.1111/j.1468-1331.1995.tb00170.x, 2, 6, (523-539), (2011).
  • Nonparametric estimator for the survival function of quality adjusted lifetime (QAL) in a three-state illness–death model, Journal of the Korean Statistical Society, 10.1016/j.jkss.2010.02.005, 39, 3, (315-324), (2010).
  • Quality-of-Life-Adjusted Survival Analysis of Concurrent Chemo Radiotherapy for Locally Advanced (Nonmetastatic) Nasopharyngeal Cancer, International Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2009.07.1702, 78, 2, (454-460), (2010).
  • Aspects médico-économiques de la pneumologie, Revue des Maladies Respiratoires Actualités, 10.1016/S1877-1203(10)70049-5, 2, 2, (205-222), (2010).
  • Parametric Estimation of Quality Adjusted Lifetime (QAL) Distribution in Simple Illness-Death Model, Communications in Statistics - Theory and Methods, 10.1080/03610920802687777, 39, 1, (77-93), (2010).
  • Empirical likelihood inference for the regression model of mean quality‐adjusted lifetime with censored data, Canadian Journal of Statistics, 10.1002/cjs.5550360309, 36, 3, (463-478), (2010).
  • Quality‐adjusted life years: origins, measurements, applications, objections, Australian Journal of Public Health, 10.1111/j.1753-6405.1993.tb00149.x, 17, 3, (272-278), (2010).
  • Using the EQ-5D Index Score as a Predictor of Outcomes in Patients With Type 2 Diabetes, Medical Care, 10.1097/MLR.0b013e3181844855, 47, 1, (61-68), (2009).
  • On induced dependent censoring for quality adjusted lifetime (QAL) data in a simple illness–death model, Statistics & Probability Letters, 10.1016/j.spl.2009.07.010, 79, 20, (2170-2176), (2009).
  • The Mean, Median, and Confidence Intervals of the Kaplan-Meier Survival Estimate—Computations and Applications, The American Statistician, 10.1198/tast.2009.0015, 63, 1, (78-80), (2009).
  • A comparison of some confidence intervals for the mean quality-adjusted lifetime with censored data, Computational Statistics & Data Analysis, 10.1016/j.csda.2009.01.013, 53, 7, (2733-2739), (2009).
  • Bayesian Regression Models for the Quality Adjusted Lifetime Data with Zero Time Duration Health States, Journal of Statistical Theory and Practice, 10.1080/15598608.2009.10411939, 3, 2, (477-487), (2009).
  • Does Topical Wound Oxygen (TWO2) Offer an Improved Outcome Over Conventional Compression Dressings (CCD) in the Management of Refractory Venous Ulcers (RVU)? A Parallel Observational Comparative Study, European Journal of Vascular and Endovascular Surgery, 10.1016/j.ejvs.2009.03.027, 38, 1, (125-132), (2009).
  • Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial, Journal of Clinical Oncology, 10.1200/JCO.2008.20.5815, 27, 26, (4268-4273), (2009).
  • Parametric estimation of quality adjusted lifetime (QAL) distribution in progressive illness–death model, Statistics in Medicine, 10.1002/sim.3556, 28, 15, (2012-2027), (2009).
  • Quality of Life, Cancer Investigation, and Clinical Practice, Cancer Investigation, 10.3109/07357909809011702, 16, 7, (478-484), (2009).
  • See more

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.